A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.
The collapse of Rubius’s first attempt to demonstrate the worth of its red blood cell platform proves that this company should never have gone public.
As a US adcom gives the strongest possible indication that oxycodegol won’t be approved, Nektar’s valuation loses 11%.
Novartis’s similarly acting fevipiprant had failed in asthma in October, and today it fails in the more important severe setting.
A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?
A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…
The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.